id_637. THE IMPACT OF 1-[(3-FLUOROPHENYL)SULFONYL]-4-(PIPERAZIN-1-YL)-1H-PYRROLO[3,2-C]QUINOLINE (FPPQ) ON MONOAMINE RELEASE IN RAT FRONTAL CORTEX
Agnieszka Wąsik1, Magdalena Białoń1, Magdalena Rak1, Paweł Zajdel2
1 Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Neurochemistry, Smętna 12, 31-343 Kraków, Poland
2 Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Str., 30-688 Kraków, Poland
INTRODUCTION: Previous studies have shown that FPPQ acts as 5-HT3/5-HT6R antagonists inhibits phencyclidine (PCP)-induced hyperactivity and displaying procognitive properties in the novel object recognition task. So, FPPQ represents a promising approach to respond to the persistent demand for higher efficacy and better compliance in treating drug-resistant schizophrenia symptoms.
AIM(S): The aim of the current study was to measure changes in monoamine (dopamine (DA), noradrenaline (NA), and serotonin (5-HT)) release in the rat frontal cortex following a single intraperitoneal administration of FPPQ (3 mg/kg) alone and in combination with PCP (5mg/kg sc) using the in vivo microdialysis method.
METHOD(S):
RESULTS: Our results indicated that FPPQ given alone decreased NA and 5-HT release (approx. 10%) in the frontal cortex. At the same time, PCP decreased NA release (approx. 10%). Combined treatment of FPPQ and PCP increased NA and 5-HT release (approx. 25%) in the frontal cortex.
CONCLUSIONS: These results demonstrated that FPPQ, whether administered alone or in combination with PCP, alters the activity of monoaminergic systems in the rat frontal cortex. This alteration may be responsible for the potentially therapeutic effects of FPPQ observed in behavioral tests.
FINANCIAL SUPPORT: The project was financed by the National Science Centre, Poland, no. 2021/43/B/NZ7/02855